The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
临床开发候选药物 CCT245737 是一种口服活性 CHK1 抑制剂,在 RAS 突变型非小细胞肺癌和 Eµ-MYC 驱动的 B 细胞淋巴瘤中显示出临床前活性。
期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.4919
Walton, Mike I; Eve, Paul D; Hayes, Angela; Henley, Alan T; Valenti, Melanie R; De Haven Brandon, Alexis K; Box, Gary; Boxall, Kathy J; Tall, Matthew; Swales, Karen; Matthews, Thomas P; McHardy, Tatiana; Lainchbury, Michael; Osborne, James; Hunter, Jill E; Perkins, Neil D; Aherne, G Wynne; Reader, John C; Raynaud, Florence I; Eccles, Suzanne A; Collins, Ian; Garrett, Michelle D
肺癌
肿瘤
T细胞
肿瘤免疫
淋巴瘤
CHK1
MYC
细胞生物学
RAS